For the third quarter of 2026, agilon health is expected to report consensus revenue of $1.46 billion and an EPS loss of -$2.01, with its current share price of $84.90 trading at a discount to the average analyst price target of $102.25.
Investors are primarily focused on the Medical Margin, a critical metric representing the company's efficiency in managing healthcare costs within its value-based physician network.
Following a series of guidance upgrades, management has raised its full-year 2026 EBITDA outlook to between $75 million and $95 million, signaling progress in its margin-recovery strategy. Market participants are closely watching for continued stabilization in medical loss ratios and the impact of recent ACO partnership expansions that have added roughly 30,000 new Medicare beneficiaries.